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Abstract
Background: Influenza infections induce considerable disease burden in young children. Biomarkers for the monitoring of
disease activity at the point-of-care (POC) are currently lacking. Recent methodologies for fluorescence-based rapid testing
have been developed to provide improved sensitivities with the initial diagnosis. The present study aims to explore the
utility of second-generation rapid testing during longitudinal follow-up of influenza patients (Rapid Influenza Follow-up
Testing = RIFT). Signal/control fluorescent readouts (Quantitative Influenza Follow-up Testing =QIFT) are evaluated as a
potential biomarker for the monitoring of disease activity at the POC.
Methods and Findings: RIFT (SOFIA) and QIFT were performed at the POC and compared to blinded RT-PCR at the National
Reference Centre for Influenza. From 10/2011-4/2013, a total of 2048 paediatric cases were studied prospectively; 273 cases
were PCR-confirmed for influenza. During follow-up, RIFT results turned negative either prior to PCR (68%), or
simultaneously (30%). The first negative RIFT occurred after a median of 8 days with a median virus load (VL) of 5.6610‘3
copies/ml and cycle threshold of 37, with no evidence of viral rebound. Binning analysis revealed that QIFT differentiated
accurately between patients with low, medium and high viral titres. QIFT increase/decrease showed 88% agreement
(sensitivity = 52%, specificity = 95%) with VL increase/decrease, respectively. QIFT-based viral clearance estimates showed
similar values compared to PCR-based estimates. Variations in viral clearance rates were lower in treated compared to
untreated patients. The study was limited by use of non-invasive, semi-quantitative nasopharyngeal samples. VL
measurements below the limit of detection could not be quantified reliably.
Conclusions: During follow-up, RIFT provides a first surrogate measure for influenza disease activity. A ‘‘switch’’ from
positive to negative values may indicate a drop in viral load below a critical threshold, where rebound is no longer expected.
QIFT may provide a useful tool for the monitoring of disease burden and viral clearance at the POC.
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Introduction
Influenza may cause significant morbidity and mortality,
especially in infants and children [1–3], who tend to exhibit high
viral loads and prolonged viral shedding [2,4,5]. In paediatric
patients, influenza may also evoke a wide range of nonspecific
symptoms, which are often difficult to predict or quantify [4,6].
Much progress has been made with respect to rapid influenza
diagnostic testing (RIDT), but standardized assessments for the
longitudinal monitoring of influenza infections are currently
lacking.
Ideally, influenza infections would be monitored in real-time, at
the point-of-care (POC). Immediate assessments would be
particularly important in the inpatient setting and during the
peak of flu season, when infection control measures are
increasingly challenging and many different physicians may be
assessing the patient over time. In influenza patients receiving
antiviral therapy, an objective POC measure of viral load should
be able to discriminate treatment success from virologic failure,
which may contribute to the emergence of drug resistance [7].
WHO and CDC guidelines recommend extending the duration of
antiviral therapy beyond five days in influenza patients with
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evidence of ongoing viral replication, immuno-compromise or
severe illness (i.e. ICU-level care) [8,9]. Considering the possibility
of antiviral resistance and viral rebound with premature termina-
tion of treatment, simple means of estimating viral clearance in
high-risk patients are needed [7,10–13]. Furthermore, clinical
trials evaluating newly developed antivirals will require objective
parameters to evaluate antiviral efficacy compared to, or in
combination with, currently available drugs [12,14].
Molecular methods and viral culture are the most commonly
used methods for the assessment of viral shedding in influenza
patients [15,16]. These assays usually require considerable
laboratory equipment and staff, and test results may take several
days to become available to the physician [6,15]. RIDT has been
developed for the immediate diagnosis of influenza infections in
the acute care setting [16–20]. RIDT are most sensitive with CT
values ,30 [21]. Second-generation RIDT (such as the SOFIA)
use fluorescence-labelled antigens combined with POC readers,
providing the advantage of standardized readouts. Evaluations in
the US, Asia and Germany revealed improved sensitivities of up to
88% compared to RT-PCR with specificities close to 100% [21–
24]. Rapid antigen tests reflect the actual amount of viral particles
in a given sample, and tend to correlate well with viral culture
results [22,25]. PCR-based methods on the other hand, include an
amplification step and are highly sensitive to the presence of
nucleic acid. With the exception of capped m-RNA PCR,
standard RT-PCR methods are not as specific for the presence
of fully intact and infectious virus particles. An ideal POC test for
the longitudinal follow-up of laboratory-confirmed influenza
infections should therefore measure disease activity based on a
critical amount of infective virus, even at the expense of lower
sensitivities compared to PCR. Rapid antigen test may be able to
fill this gap. During the process of viral clearance, the loss of
antigen-positivity may indicate successful treatment or ‘‘overcom-
ing’’ of natural infection, whereas RT-PCR results tend to remain
positive for extended periods of time, even beyond resolution of
clinical symptoms [7].
We hypothesized that qualitative (‘‘positive’’/‘‘negative’’) as well
as quantitative (‘‘signal over control’’) luminescent readouts from
second-generation rapid antigen tests may prove to be useful as an
immediate estimate of virus burden and disease activity. We used
SOFIA as an example of a simple rapid antigen test that can be
performed by nurses or doctors at the bedside.
The present study aims to evaluate the utility of:
i) ‘‘Rapid Influenza Follow-up Testing’’ (RIFT) for the (quali-
tative) monitoring of influenza infections over time as well as
ii) ‘‘Quantitative Influenza Follow-up Testing’’ (QIFT) as a
potential biomarker for the monitoring of influenza disease
activity (virus burden) at the POC.
Methods
Ethics Statement
Ethical approval was obtained from the Charite´ Institutional
Review Board (EA 24/008/10). Informed consent procedures
were waived for enhanced patient monitoring in the context of a
quality management (QM) program.
Study design and data collection
This prospective evaluation study was performed in the context
of a QM program at the Charite´ Department of Paediatrics in
collaboration with the National Reference Centre for Influenza at
the Robert Koch Institute (RKI). From October 1, 2011 to April
30, 2013, all patients fulfilling pre-defined criteria for influenza-
like illness (fever $38uC and $ one respiratory sign or symptom)
were assessed consecutively by a specifically trained QM team
[7,21]. Cases were included if i) the patient was 0–18 years of age,
and ii) influenza infection was confirmed by RT-PCR in the
national reference laboratory. Cases were excluded from this
analysis in case of: i) simultaneous infection with more than one
influenza type or subtype [26], or ii) inability to obtain
nasopharyngeal samples.
Follow-up Testing
Members of a specifically trained QM team obtained nasopha-
ryngeal samples, with rapid antigen tests (SOFIA) performed at the
bedside. Patients with laboratory-confirmed influenza were
scheduled for follow-up testing every two to three days, until at
least one negative RIFT result was obtained or longer, if indicated.
Basic clinical parameters and treatment with neuraminidase
inhibitors were recorded. The respective clinician on duty made
antiviral treatment decisions independently. With each rapid
antigen test, blinded RT-PCR was performed in parallel at the
RKI.
RIFT. Fluorescence-based RIFT was performed immediately
at the POC and according to the manufacturer’s protocol for the
SOFIA Influenza A+B FIA test kit (Quidel Inc., San Diego, CA,
USA). With each test, the SOFIA luminescent reader provided
print-outs with qualitative test results (influenza A or B positive/
negative), which were recorded and communicated without delay
to the patient or parent as well as to the physician on duty.
QIFT. QIFT-values were calculated for each rapid antigen
test based on the relationship between the influenza A and B test
lines’ fluorescence intensities and the cut-offs for each analyte with
the SOFIA test. The resulting signal over control values (SCo)
generated by the SOFIA POC reader ranged from 0 to 400. The
limit of detection (LOD) with QIFT is 1; values .1 were
considered positive.
RT-PCR and Viral Load (VL) Determination. Qualitative
and quantitative RT-PCR were performed as described recently
[7]. Briefly, nasopharyngeal swabs were washed out in cell culture
medium and RNA was extracted either by using the MagAttract
Viral RNA 48 Kit (Qiagen), the RTP RNA/DNA Virus Minikit
(Invitek), or the MagnaPure 96 DNA and viral NA small volume
kit (Roche). After random reverse transcription complementary
DNA, primer and probes targeting the M, HA and NA genes were
used for detection and further subtyping of influenza [27]. The
RT-PCR cycle threshold (CT) values obtained for each influenza
positive sample were analysed comparatively with serially diluted
plasmid standards. All reactions were performed using the Light
Cycler 480 real-time PCR system (Roche). CT values obtained
with influenza negative samples were defined as 45 for mathe-
matical analyses. The limit of detection for RT-PCR (LODPCR)
depends on the targeting gene and was determined to be 2–15
genome equivalents per reaction (95% detection probability) [27].
Regarding dilution factors due to sample preparation, RNA
extraction, cDNA synthesis, and PCR performing, the limit of
viral load quantitation (LOQ) was estimated to be 1000 copies/
ml. This value was defined as LODVL, below which the calibration
curve is no longer valid and quantitative values are not reliable.
Comparison of virus load assessments based on CT versus
quantitative PCR at the National Reference Centre showed a
correlation of 0.95 (Spearman, p-value,0.0001; Figure S1). With
a high correlation between the two methods of VL assessment in
the reference laboratory, it was decided to use CT for the QIFT/
PCR correlation analyses, with the advantage of a lower LODPCR
compared to LODVL.
Rapid Follow-Up Testing for Influenza at the POC
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Data Analysis
Data analysis and reporting were conducted in accordance with
the STARD guidelines [28], wherever applicable. The STARD
checklist is provided in the Supplementary Materials (Text S1).
The STARD was chosen as the most appropriate standard
available, even though the reported study pertains to longitudinal
follow-up of patients with established diagnoses rather than
diagnostic accuracy. The diagnostic accuracy including sensitivi-
ties and specificities of SOFIA RIDT in relation to PCR in the
same setting has been published elsewhere [21].
RIFT compared to longitudinal PCR results. All patients
with at least one positive RIFT and completed follow-up series
were included in the analysis. Qualitative RIFT data for each
patient during follow-up were compared to the corresponding CT
value in the RT-PCR.
Three key time points were determined for each disease
episode:
i) TMV = Time point of maximum viral load/ lowest CT
ii) TLP = Time point of last positive RIFT
iii) TFN = Time point of first negative RIFT.
The respective time points TMV, TLP, and TFN were plotted
against the respective CT values at TMV, TLP, and TFN. The y-axis
was inserted at the time point where the switch from TLP to TFN
occurred ( = ‘‘Switch Day’’).
RIFT compared to viral culture. Overall rates of agree-
ment and kappa scores were calculated (Stata Version 11.2),
comparing the time period required for RIFT and viral culture to
become negative, respectively.
QIFT and clinical parameters. For correlation analysis
between QIFT and clinical presentation, the following clinical
parameters were chosen: a) maximum body temperature, b) CRP
and c) presence of tachypnea (according to age-adjusted WHO
criteria).
Correlation analyses for a) and b) were conducted using the
Spearman rank correlation test. For analysis of c), a non-
parametric test (Mann Whitney) was used.
QIFT /PCR Correlation Analysis. For QIFT/PCR corre-
lation analysis, two correlation plots were generated:
i) First, all values were included. Any QIFT values , LODQIFT
were set equal to the LODQIFT as the most conservative
estimate. Values = 0 (i.e. virus not detectable by either
method) were set to 0.
ii) A second analysis was performed excluding any values ,
LOD.
Correlation analyses between continuous variables were con-
ducted using the Spearman rank correlation test.
Categorizing viral load based on QIFT. Binning analyses
were performed for the categorization (‘‘binning’’) of median virus
load in relation to different QIFT categories (negative, low,
moderate, and high QIFT). Continuous variables were compared
between different categories (‘‘bins’’) using non-parametric tests
(Mann Whitney, Kruskal Wallis).
For comparison between QIFT and CT values, a ‘‘sliding
window plot’’ was generated using MATLAB 7.14 (MathWorks
Inc., Natick, MA): All simultaneous measurements of QIFT vs.
CT were sorted by the respective QIFT in ascending order. Every
30 consecutive QIFT values denote a sliding window.
Estimating viral load kinetics based on QIFT and
PCR. Lacking a reference standard for the assessment of viral
shedding/antigen clearance over time, overall rates of agreement
and kappa scores were calculated comparing QIFT increase or
decrease to PCR increase or decrease over time [29–32]. Each
sequence of 2 consecutive samples from the same patient was
included in the analysis. A trend in viral load was defined as
increase or decrease if rates of change in relation to the previous
measurement in the same patient exceeded 10%.
Viral clearance dynamics with and without
treatment. Viral clearance dynamics with and without treat-
ment were computed for VL (CLVL) and QIFT (CLQIFT). All cases
with at least two positive samples with both VL and QIFT
measurements available ( =QIFT population) were included. In
patients receiving antivirals, treatment had to be completed and
baseline swabs had to be obtained within 24 hours of treatment
initiation. Patient-specific CLVL and CLQIFT were estimated with
calculated quantitative values even below LOD, using the
optimization routine lsqcurvefit in MATLAB version 7.10 (Math-
Works Inc., Natick, MA) and a weighted least-square criterion to
minimize residual error. Details are provided in the Text S2.
Results
Study population
From October 1, 2011 to April 30, 2013, a total number of
2048 disease episodes were assessed and documented prospective-
ly; of these, 278 (13.6%) cases were laboratory-confirmed for
influenza by PCR. Three cases with dual influenza infection (A/A,
A/B and B/B) and two patients unable to provide nasopharyngeal
samples were excluded, leaving for analysis 273 cases of
laboratory-confirmed influenza with serial swabs available. (Two
patients experienced two independent disease episodes due to
different influenza viruses, both were included as separate cases in
the analysis.)
Case characteristics at the time of enrolment with each disease
episode are displayed in Table 1. Among 273 influenza cases
( = total population) 55 were ‘‘late presenters’’, i.e. patients who
appeared in the emergency room late in the course of illness, after
loss of their antigen-positive status in the RIFT, which usually
requires intact viral particles (as opposed to nucleic acid) and
higher viral loads compared to PCR. Overall, 178 patients
completed the full follow-up program until at least one negative
RIFT was obtained (RIFT population), resulting in an overall
completion rate of 85%. For QIFT/PCR correlation and binning
analyses, all 669 quantitative antigen measurements were includ-
ed. A total of 210 cases fulfilled QIFT population criteria
(availability of .=2 positive samples with both, VL and QIFT
measurements). Among these, 183 patients were without antiviral
therapy, and 27 completed oseltamivir therapy. There was no
significant correlation between the decision to use antivirals and
either the number of symptoms, the duration of illness, or the
presence of underlying conditions (p = 0.595, p= 0.781 and
p= 0.797, respectively).
Data Analysis
RIFT results tend to turn negative prior to PCR. The
qualitative results obtained with rapid influenza follow-up testing
(RIFT) were compared to cycle thresholds with RT-PCR. The key
follow-up time points TMV, TLP, and TFN were determined for
each disease episode and plotted against the corresponding CT
values, as depicted in Figure 1.
During follow-up visits, the first negative RIFT was observed at
a median of 8 days (range 2; 19) with a median CT of 37 (range
45; 23) and a median VL of 5.6610‘3 (range 0; 78.4610‘3). The
first negative RIFT result was consistently observed prior to (68%)
or simultaneous with (30%) a first negative RT-PCR result. There
Rapid Follow-Up Testing for Influenza at the POC
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were only 4 instances (2%) where a positive RIFT was not
confirmed by PCR, which was attributed to contamination of
infant samples with RNAses. No cases of viral rebound were
observed. The ‘‘Switch Day’’ from positive to negative RIFT,
illustrated by insertion of the y-axis between TLP and TFN,
corresponded to a CT value of 33.
RIFT results correlate well with virus culture
In 118 cases, at least two swabs with viral culture data in
addition to RIFT were available, with a ‘‘switch’’ from positive
RIFT and/or culture to negative RIFT and/or culture. Time
required for RIFT to become negative from a previously positive
value was 5.9763.16 days; (range 2; 18).Time required for viral
culture to become negative was 5.3162.67 days (range 2; 14).
We observed an overall rate of agreement of 77.97% between
the time period required for RIFT to become negative and time
period required for viral culture to become negative (kappa= 0.75;
p-value,0.0001). With respect to correlation analysis between
time periods, we observed a Spearman’s correlation of 0.803
between the two time periods (p-value,0.0001).
No significant correlation between QIFT values and
clinical parameters. QIFT showed no significant correlation
or association to the following clinical parameters: a) maximum
body temperature (Spearman Rho=20.027, p = 0.667), b) CRP
(Spearman Rho=20.087, p= 0.338) and c) presence of tachy-
pnea (Mann Whitney, p = 0.154).
QIFT values close to the LOD correlate poorly with
PCR. All quantitative measurements obtained during longitudi-
nal follow-up amounted to 669 measurements with QIFT and
matching CT values. QIFT/PCR correlations are depicted in
Figure 2. QIFT showed a significant correlation with CT of 0.69
(Spearman, p-value,0.0001) with QIFT values , LOD set to
LOD =1 as the most conservative estimate. Following the RIFT
observations illustrated above, it is expected that during longitu-
dinal follow-up (of which all values are included in this plot), RIFT
Table 1. Characteristics of eligible PCR- confirmed influenza cases.
Category Subcategory Total cases Age ,2 years Age 2–5 years Age .5 years
(%) (%) (%) (%)
Total N 273 82 96 95
Gender male 152 47 49 56
(55.7) (58.3) (51.0) (58.9)
female 121 35 47 39
(44.3) (42.7) (49.0) (41.1)
Underlying condition pulmonary 26 7 7 12
(9.5) (8.5) (7.3) (12.6)
cardiac 20 4 7 9
(7.3) (4.9) (7.3) (9.5)
endocrine 13 1 4 8
(4.8) (1.2) (4.2) (8.4)
hepatorenal 4 1 0 3
(1.5) (1.2) (0) (3.2)
neurologic 19 3 6 10
(7.0) (3.7) (6.3) (10.5)
immuno- suppression 9 0 2 7
(3.3) (0) (2.1) (7.4)
hematologic 2 1 0 1
(0.7) (1.2) (0) (1.1)
Prematuritya 33 13 13 7
(12.1) (15.9) (13.5) (7.4)
Treatment with Oseltamivir treated 33 16 11 6
(12.1) (19.5) (11.5) (6.3)
untreated 240 66 85 89
(87.9) (80.5) (88.5) (93.7)
Influenza type/ subtype A(H1N1)pdm09 70 27 23 20
(25.6) (32.9) (24.0) (21.1)
A(H3N2) 112 38 47 27
(41.0) (46.3) (49.0) (28.4)
B 91 17 26 48
(33.3) (20.7) (27.1) (50.5)
a,37 gestation weeks.
doi:10.1371/journal.pone.0092500.t001
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will turn negative prior to PCR. Figure 2 illustrates that QIFT
values near or below the LODQIFT correlated poorly with PCR,
compared to higher QIFT values.
Categorization based on QIFT provides useful estimate of
virus burden. For the categorization of virus load based on
low, moderate and high QIFT values, binning analyses were
performed: QIFT readings were categorized into the following
‘‘bins’’: ‘‘negative’’ (0–1), ‘‘low’’ (i.e..1–100), ‘‘moderate’’ (.100–
199), and ‘‘high’’ (.199–400). Median CT values differed
Figure 1. Comparison of CT values over time in relation to RIFT. The insertion of y-axis reflects the ‘‘switch’’ from positive to negative RIFT.
doi:10.1371/journal.pone.0092500.g001
Figure 2. Comparison of CT versus QIFT. LODQIFT was defined as QIFT = 1.
doi:10.1371/journal.pone.0092500.g002
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significantly with respect to the four QIFT categories (Mann
Whitney, Kruskal Wallis, p-value,0.0001), see Figure 3.
A Sliding Window Plot was generated to evaluate the
performance of any particular QIFT in predicting CT values
(Figure 4). The resulting graph illustrates a percentiles curve for
the estimation of CT based on QIFT, including medians for the
respective QIFT value. Please note that with 669 samples, there is
a relatively broad coefficient of variation of approximately 20%.
Up- and downward trends in virus load are reflected
similarly by PCR and QIFT. To determine trends in virus
burden based on quantitative PCR versus QIFT, rates of
agreement between ‘‘QIFT-increase’’, ‘‘QIFT-decrease’’, ‘‘VL-
increase’’, and ‘‘VL-decrease’’ were calculated. Overall agreement
was 88% (kappa= 0.49; p-value,0.0001), see Table 2.
Viral clearance rates in treated and untreated patients
may be monitored using QIFT
Median clearance rates CLVL and CLQIFT in QIFT patients
with and without antiviral treatment are depicted in Figure 5.
Overall, CLQIFT showed slightly lower, but similar values
compared to CLVL. In treated patients, median clearance rates
were 1.02/day when determined by PCR (CLVL), and 0.56/day
when measured by QIFT (CLQIFT) (Spearman: 0.26; p = 0.1912).
In untreated cases, the median CLVL was 0.97/day and median
CLQIFT was 0.76/day (Spearman: 0.24; p = 0.0013). In patients
receiving antiviral therapy, viral clearance rates based on PCR
(CLVL) showed less variability (range 0.08; 2.49) compared to
untreated patients (range 24.70; 4.84). The same observation held
true with respect to viral clearance rates based on antigen testing
Figure 3. Binning analysis: Estimation of CT, median values based on categorized QIFT readouts. The following QIFT categories were
used: ‘‘Negative QIFT’’: 0 to 1 (n = 333). ‘‘Low QIFT’’: .1 to 100 (n = 254). ‘‘Moderate QIFT’’: .100 to 199 (n = 56). ‘‘High QIFT’’: .199 (n = 26).
doi:10.1371/journal.pone.0092500.g003
Figure 4. Sliding Window Graph: Binning of median CT values
and ranges/percentiles based on median QIFT.
doi:10.1371/journal.pone.0092500.g004
Table 2. Rates of agreement between QIFT and VL increase/
decrease.
QIFT q QIFT Q
VL q 29 31
VL Q 16 320
Rate of Agreement 64% 91% 88%
doi:10.1371/journal.pone.0092500.t002
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(CLQIFT) ranging from 20.07 to 1.62 and from 22.36 to 5.03 in
treated versus untreated patients, respectively.
Discussion
Statement of Principal Findings
We report a first prospective study investigating ‘‘loss of antigen
positivity’’ as a POC parameter for the longitudinal monitoring of
influenza patients. During follow-up, rapid antigen testing using
fluorescence-based laminar flow tests (RIFT) may provide a
practical surrogate measure for influenza disease activity. ‘‘Loss of
antigen positivity’’ in RIFT may indicate a drop in viral load
below a critical threshold, where viral rebound is no longer
expected. It may also indicate loss of infectivity as reflected by viral
culture turning negative simultaneously with RIFT in most cases.
Quantitative readouts from the same rapid test (QIFT) show
potential as a valuable biomarker for the monitoring of virus
burden over time, with the advantage of obtaining results
immediately at the POC. QIFT may also be able to discriminate
between disease progression (VL increase) and resolution (VL
decrease). In patients receiving antiviral therapy, QIFT can be
used to monitor treatment success versus failure and/or risk of
antiviral drug resistance by estimating viral clearance rates under
therapy [7].
Rapid Follow-up Testing in Context
For effective infection control measures and to reduce morbidity
and mortality, isolation precautions are imminent. Antiviral
treatment when indicated needs to be initiated as timely as
possible [9,33]. The need to diagnose treatable conditions with
high disease burden has driven the development of diagnostic
assays to be used at the POC. In contrast to first-generation
RIDT, where sensitivities were still relatively low and user-
dependent [34], second-generation RIDT combine improved
sensitivities with objective automated read-outs [21,22,24].
Recent fluorescent-based RIDT such as SOFIA issue qualitative
(positive/negative) results based on qualitative signal over control
measurements. While RIDT have been licensed for the initial
diagnosis of influenza at the POC [1,6,17], this pilot study
demonstrates that qualitative (RIFT) and quantitative (QIFT)
fluorescence-based antigen testing may both be useful for the
longitudinal monitoring of influenza infections over time.
Strengths and Limitations of the Study
The retention rate in this study was .85%, which is very high
for an observational setting. For the evaluation of rapid influenza
testing as a follow-up tool (RIFT) and QIFT-based clearance rates
however, a sufficient number of follow-up time points was
required. Hence, smaller subsets of patients were included in
Figure 5. Comparison of viral clearance rates for CLVL versus CLQIFT and for treated versus untreated patients. Variance in viral
clearance rates for quantitative is smaller in treated than in untreated patients, for both VL and QIFT.
doi:10.1371/journal.pone.0092500.g005
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these analyses, representing 65% in RIFT and 80% in QIFT
clearance rate calculations.
During longitudinal follow-up, RIFT turned negative consis-
tently with, or after the PCR. It has to be borne in mind, that PCR
and antigen tests measure different aspects of the same disease.
While PCR-based (amplification) methodologies may be sensitive
enough to detect even small amounts of nucleic acid over extended
periods of time, direct antigen testing may provide an immediate
(linear) estimate of virus burden during the acute phase of the
disease only. It has been known that RIDT correlate better with
viral culture than with PCR. It was therefore expected that the
agreement between RIFT and PCR would decline during
longitudinal follow-up (until both test are negative), whereas the
duration of viral culture positivity may correlate well with antigen
positivity [22,25]. It is also to be expected that the lower sensitivity
of rapid antigen testing compared to PCR would affect the QIFT/
PCR correlation, especially later during the course of illness, when
‘‘loss of antigen positivity‘‘ has already occurred and RIFT has
turned negative ( =QIFT,1). VL measurements from PCR-
positive samples below the LODQIFT could however not be
quantified reliably. For utmost transparency, values below the
LODQIFT were included in the analyses, but set to equal the
highest possible value ( = LOD) as the most conservative estimate.
Reversely, negative QIFT corresponded well with negative PCR
results.
QIFT and PCR both rely on the semi-quantitative measure-
ment of virus load in nasopharyngeal samples – unlike in the case
of HIV and hepatitis VL monitoring, where plasma virus loads are
followed. To minimize variability with nasopharyngeal sampling,
all RIFT/QIFT assays were performed immediately at the POC,
and by a specifically trained QM team. Samples were delivered
immediately to the RKI for blinded PCR analyses. The value of
optimized sampling procedures has been demonstrated in previous
evaluations establishing the sensitivity and specificity of the same
assay (SOFIA for influenza A and B) in the same QM setting [21].
Use of QIFT and RIFT in less controlled settings may yield
different results. Even if sampling has been optimized however, it
must be noted that nasopharyngeal samples may not always reflect
the virus burden present in the lower respiratory tract in critically
ill patients, where VL may be elevated in patients infected with
influenza viruses [11,35]. Also, viral shedding in the lower airways
is known to be prolonged in adult patients with pneumonia or
immuno-compromise. In these patients, relapse of disease can
occur if therapy is stopped based on cessation of upper airway
replication alone [11]. This however, would require broncho-
alveolar lavage procedures, which would neither be ethical nor
feasible for the routine follow-up of paediatric influenza patients
(unless intubated and critically ill). The present study does not
allow for comparison of specific patient subpopulations. Further
research in specific risk groups is needed.
Future analyses in specific subpopulations may compare the 3-
way relationship between of PCR-positivity, antigen-positivity and
viral culture in influenza patients with extreme disease presenta-
tions or different levels of immunosuppression.
Future Perspectives
The results of the binning analyses demonstrate the practical
value of QIFT for the monitoring of influenza disease activity at
the POC. For QIFT to be used in clinical practice in the future,
quantitative readings should be issued as four categories: negative,
low, moderate, and high virus burden. QIFT as a follow-up tool
could be optimized further, if the fluorescent reader provided a
standardized display of trends in virus burden in relation to
previous measurements in the same patient, or VL estimates as
demonstrated in the binning and sliding window plots. Having
immediate estimates of virus burden available at the POC will be
of great value to support a personalized approach to the
management of infants and immuno-compromised individuals
with influenza infection who often exhibit elevated virus titres and
prolonged virus shedding [2,4,5]. Previous studies have shown that
virus burden cannot be estimated based on clinical appearance
alone. It has further been reported that viral shedding may persist
beyond cessation of clinical symptoms [4,36]. Objective param-
eters such as RIFT and QIFT may facilitate individualized
therapy of influenza with estimates of virus burden available
immediately at the POC.
The decision whether or not to treat with antivirals in this QM
setting, was left up to the clinician in charge. Interestingly, only a
small proportion (12.1%) of patients with laboratory–confirmed
influenza received neuraminidase inhibitor therapy. For all treated
patients oseltamivir was prescribed. In the described setting,
zanamivir is restricted to antiviral therapy in ICU patients or
patients unable to take p.o. medicine. There was no evidence of
correlation between treatment decision and patients’ clinical
symptoms, underlying conditions or late appearance to the
hospital. With new antivirals under development, it might be of
value to pursue QIFT as a follow-up tool in randomized controlled
clinical trials.
Current recommendations by health authorities regarding
established neuraminidase inhibitor therapies include a standard
five-day course of treatment with a possible extension to ten days
in cases of ‘‘ongoing viral replication’’ [8,9]. Once antiviral
therapy has been terminated, it should not be restarted. This
implies that the decision whether to stop or adjust antiviral therapy
has to be made on day five, at the POC. Relative under-dosing
and/or premature treatment termination harbour the risk of
promoting antiviral drug resistance [10,13].
Previous studies have indicated that during antiviral therapy, a
less-than-expected slope of decline in VL might indicate resistance
development [7]. QIFT shows potential as a simple tool for the
real-time monitoring of treatment success at the POC: QIFT-
based viral clearance estimates (CLQIFT) showed similar ranges
and percentiles compared to PCR-based VL estimates (CLVL).
CLVL however may be more accurate in lower ranges and with
prolonged treatment. Further analyses in larger cohorts of treated
influenza patients may be required to determine the exact
relationship between CLQIFT and CLVL. The interesting observa-
tion that antiviral treatment may reduce intra-individual variation
in viral clearance rates with both CLQIFT and CLVL warrants
further investigation.
Additional studies may be undertaken to investigate the cost-
effectiveness of individualized antiviral therapy as well as the
longitudinal monitoring of virus burden in infants, high risk and
immuno-compromised individuals. The high retention rate in this
QM program indicates that the availability follow-up data at the
POC and the immediate feedback and reassurance to concerned
patients and families may have a positive impact on patient
satisfaction.
Conclusions
RIFT and QIFT show promise as simple and objective tools for
the real-time monitoring of influenza infections over time. RIFT
may be used as an objective measure for ‘‘loss of antigen
positivity’’, whereas QIFT provides a useful estimate of viral
clearance over time. The ability to monitor disease activity at the
POC may have important implications for infection control. It
may also facilitate the individualized management of infants and
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young children as well as immuno-compromised patients under
antiviral therapy. Future studies in larger cohorts of patients will
explore the practical implications of RIFT and QIFT in different
clinical and demographic settings.
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